Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

865 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Diagnostic approach to IBD.
Vermeire S, Peeters M, Rutgeerts P. Vermeire S, et al. Hepatogastroenterology. 2000 Jan-Feb;47(31):44-8. Hepatogastroenterology. 2000. PMID: 10690584 Review.
Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease.
Esters N, Vermeire S, Joossens S, Noman M, Louis E, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, Poulain D, Bossuyt X, Rutgeerts P; Belgian Group of Infliximab Expanded Access Program in Crohn's Disease. Esters N, et al. Among authors: vermeire s. Am J Gastroenterol. 2002 Jun;97(6):1458-62. doi: 10.1111/j.1572-0241.2002.05689.x. Am J Gastroenterol. 2002. PMID: 12094865 Free article.
NOD2/CARD15 does not influence response to infliximab in Crohn's disease.
Vermeire S, Louis E, Rutgeerts P, De Vos M, Van Gossum A, Belaiche J, Pescatore P, Fiasse R, Pelckmans P, Vlietinck R, Merlin F, Zouali H, Thomas G, Colombel JF, Hugot JP; Belgian Group of Infliximab Expanded Access Program and Fondation Jean Dausset CEPH, Paris, France. Vermeire S, et al. Gastroenterology. 2002 Jul;123(1):106-11. doi: 10.1053/gast.2002.34172. Gastroenterology. 2002. PMID: 12105838 Free article.
Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease.
Vermeire S, Louis E, Carbonez A, Van Assche G, Noman M, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Rutgeerts P; Belgian Group of Infliximab Expanded Access Program in Crohn's Disease. Vermeire S, et al. Am J Gastroenterol. 2002 Sep;97(9):2357-63. doi: 10.1111/j.1572-0241.2002.05991.x. Am J Gastroenterol. 2002. PMID: 12358256 Free article.
Optimizing anti-TNF treatment in inflammatory bowel disease.
Rutgeerts P, Van Assche G, Vermeire S. Rutgeerts P, et al. Among authors: vermeire s. Gastroenterology. 2004 May;126(6):1593-610. doi: 10.1053/j.gastro.2004.02.070. Gastroenterology. 2004. PMID: 15168370 Review.
Medical treatment of inflammatory bowel diseases.
Van Assche G, Vermeire S, Rutgeerts P. Van Assche G, et al. Among authors: vermeire s. Curr Opin Gastroenterol. 2005 Jul;21(4):443-7. Curr Opin Gastroenterol. 2005. PMID: 15930985 Review.
865 results